Cash and cash equivalents

Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, August 3, 2021

Revenue: Net revenue from sales of ZULRESSO was $1.6 million in the second quarter of 2021 compared to $1.1 million in the same period of 2020.

Key Points: 
  • Revenue: Net revenue from sales of ZULRESSO was $1.6 million in the second quarter of 2021 compared to $1.1 million in the same period of 2020.
  • Restructuring Expenses: Sage had no restructuring expenses in the second quarter of 2021 compared to $28.4 million in the second quarter of 2020.
  • Sage anticipates cash, cash equivalents, and marketable securities of more than $1.7 billion at end of 2021.
  • Sage will host a conference call and webcast today, Tuesday, August 3, at 8:00 am ET to discuss its second quarter 2021 financial results and recent corporate updates.

Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 2, 2021

and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced recent business progress and second quarter 2021 financial results.

Key Points: 
  • and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced recent business progress and second quarter 2021 financial results.
  • We are pleased with the progress made in the second quarter, said Mike Cola, Chief Executive Officer of Cerecor.
  • We look forward to the second half of 2021 with multiple data readouts including the second cohort of CERC-002 in Crohns disease.
  • Second Quarter 2021 Financial Update:
    As of June 30, 2021, Cerecor had $40.4 million in cash and cash equivalents, representing a $21.5 million increase as compared to December 31, 2020.

Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Retrieved on: 
Monday, August 2, 2021

We are pleased to have achieved this milestone, said Mike Cola, Chief Executive Officer of Cerecor.

Key Points: 
  • We are pleased to have achieved this milestone, said Mike Cola, Chief Executive Officer of Cerecor.
  • With the closing of the second tranche, the Company has drawn down a total of $30 million under its debt financing agreement with Horizon.
  • An additional $5 million may be funded upon Cerecor achieving certain predetermined milestones.
  • As of June 30, 2021, the Company had $40.4 million in cash and cash equivalents, which excludes the second drawdown of $10 million under the debt financing agreement.

Align Technology Announces $75 Million Accelerated Stock Repurchase Program

Under the terms of the ASR, Align will receive an initial delivery of approximately 86,200 shares.

Key Points: 
  • Under the terms of the ASR, Align will receive an initial delivery of approximately 86,200 shares.
  • The ASR transaction is expected to be completed by October 26, 2021 and will be funded with Aligns cash on hand.
  • As of March 31, 2021, Align had approximately 79.1 million shares outstanding and $1.1 billion in cash and cash equivalents.
  • Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

Retrieved on: 
Monday, August 2, 2021

Based on its current assumptions, DBV expects that its current cash and cash equivalents will support its operations until the second half of 2022.

Key Points: 
  • Based on its current assumptions, DBV expects that its current cash and cash equivalents will support its operations until the second half of 2022.
  • DBV Technologies S.A. (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter of 2021.
  • The quarterly financial statements were approved by the Board of Directors on July 30, 2021.
  • In 2Q 2021, we have made significant progress in developing and selecting modified Viaskin Peanut patches, said Daniel Tasse, Chief Executive Officer, DBV Technologies.

ORYZON Reports Results and Corporate Update for First Half Ended June 30, 2021

Retrieved on: 
Thursday, July 29, 2021

Furthermore, vafidemstat also showed clear anti-inflammatory responses in moderate and severe CoVID-19 patients in our two-arm, randomized Phase II study, ESCAPE.

Key Points: 
  • Furthermore, vafidemstat also showed clear anti-inflammatory responses in moderate and severe CoVID-19 patients in our two-arm, randomized Phase II study, ESCAPE.
  • The preliminary results corresponding to the 30 months of the study, presented at the EHA 2021 congress, show robust signs of clinical efficacy, with ORR of 83%, of which 67% are CR/CRi.
  • The company plans to present a new clinical update on ALICE at the ASH 2021 congress.
  • Cash, cash equivalents and marketable securities totaled $40.1 million as of June 30, 2021, compared to $54.9 million as of June 30, 2020.

GigaMedia Announces Second-Quarter 2021 Financial Results

Retrieved on: 
Friday, July 30, 2021

Net lossin the second quarter of 2021 was $0.84 million, decreased from a net loss of $0.87 million in the first quarter.

Key Points: 
  • Net lossin the second quarter of 2021 was $0.84 million, decreased from a net loss of $0.87 million in the first quarter.
  • GigaMedia maintained its solid financial position, with cash, cash equivalents and restricted cash amounted to $43.7 million, or $3.95 per share, as of June 30, 2021.
  • Reconciliations to the GAAP equivalents of the non-GAAP financial measures are provided on the attached unaudited financial statements.
  • The financial statements from which the financial results reported in this press release are derived have been prepared in accordance with U.S. GAAP, unless otherwise noted as "non-GAAP," and are presented in U.S. dollars.

Inventiva Reports First-Half of 2021 Financial Information

Retrieved on: 
Wednesday, July 28, 2021

As of June 30, 2021, Inventivas cash and cash equivalents stood at 93.6 million compared to 107.8 million as of March 31, 2021 and 113.02 million as of December 31, 2020.

Key Points: 
  • As of June 30, 2021, Inventivas cash and cash equivalents stood at 93.6 million compared to 107.8 million as of March 31, 2021 and 113.02 million as of December 31, 2020.
  • Net cash used from investing activities amounted to 1.2 million in the first half of 2021 compared to 1.0 million for the same period in 2020.
  • Over the first semester of 2021, the Company recorded a positive exchange rate effect on cash and cash equivalent of 1.2 million.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

Firsthand Technology Value Fund Discloses Preliminary NAV of $15.57 Per Share as of June 30, 2021

SAN JOSE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the Fund), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of June 30, 2021, was $15.57.

Key Points: 
  • SAN JOSE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the Fund), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its preliminary NAV, as of June 30, 2021, was $15.57.
  • As of June 30, 2021, the Funds investment in Pivotal consisted of 23,089,506 shares of common stock equivalents (CDIs) and represented approximately 25.8% of the Funds preliminary net assets.
  • The Funds preliminary net assets as of June 30, 2021, include cash and cash equivalents of approximately $0.50 per share.
  • Firsthand Technology Value Fund, Inc. is a publicly traded venture capital fund that invests in technology and cleantech companies.

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

Retrieved on: 
Thursday, July 22, 2021

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update.
  • Cash, cash equivalents, restricted cash, and short-term investments of approximately $76.2 million as of June 30, 2021.
  • "As the broader economy opens up, our preliminary second quarter results reflect strong sequential performance across our business, growth relative to the second quarter of 2019, and record SINUVA revenues, said Thomas A.
  • Intersect ENT announced today that it entered into a $60 million secured term loan agreement with a fund managed by Deerfield Management Company L.P. (Deerfield).